Becanex GmbH and Four 20 Pharma GmbH have entered into a collaboration to systematically evaluate the inhalation suitability of Becanex’s PIEX concentrates within Curaleaf’s Que Medical Inhalation Device (QMID). The objective is a scientifically robust assessment of technical compatibility, aerosol performance, and pharmaceutical quality within a closed, controlled inhalation platform. An initial feasibility study has already delivered highly positive results.

Tino Haack, Managing Director of Four 20 Pharma GmbH, states:

"For us, this cooperation is a logical next step in providing patients with another scientific alternative to cannabis flowers. Cannabis therapy is characterized by its wide range of applications. We consider it very important to provide patients with diverse therapeutic options tailored to their individual needs. Especially when it comes to inhalation, consistent dosing can make a real difference in care. The fact that we have found a raw material partner in Becanex's PIEX Concentrates, whose quality standards are in line with those of our QMID system, makes this collaboration particularly promising for us. We now want to scientifically substantiate this together."

Sebastian Kamphorst, Managing Director of Becanex GmbH, adds:

“The combination of our PIEX Concentrates with the QMID system offers patients a consistent, easy-to-use, and safe therapeutic option for breakthrough pain. The stable terpene and cannabinoid profile provides a discreet alternative to the vaporization of cannabis flower. We look forward to jointly exploring this potential with Four 20 Pharma while advancing our commercial partnership.”

Study Design and Analytical Focus

The studies comprise a multi-stage testing program. The tests are conducted in accordance with established analytical methods and quality standards to ensure a reproducible, safe, and therapeutically controllable application.

Key Properties of PIEX Concentrates

PIEX extracts are produced using a particularly gentle manufacturing process designed to minimize thermal stress. This method preserves the representative cannabinoid and terpene composition of the cannabis flower while avoiding the extraction of high‑molecular‑weight lipids. The resulting extracts exhibit defined composition, high purity, and physical stability suitable for inhalation delivery formats.

Characteristics of the QMID Inhalation System

The QMID system is a closed, precision‑engineered medical inhalation device developed for the controlled administration of standardized cannabis extracts. Its technology ensures consistent dosing and reduces inter‑individual variability in inhaled drug delivery — addressing key requirements for modern extract‑based formulations in the medical cannabis sector.

Commercial Partnership

Parallel to the scientific evaluation, the two companies have agreed on a reciprocal distribution partnership. Four 20 Pharma will add Becanex’s PIEX Concentrates to its product portfolio, while Becanex will distribute the QMID system and corresponding cartridges. The shared goal is to expand access to standardized inhalable cannabis extracts as an alternative to cannabis flower and to support the development of innovative administration forms.

We will be pleased if you include our press release in your coverage. We are available for further information, interviews, or technical inquiries.

Contact for Media Enquiries

Four 20 Pharma GmbH

Heyst GmbH, Oliver Kirch, presscontact, 420pharma@heyst.com

About Four 20 Pharma GmbH

Four 20 Pharma GmbH was founded in 2018 and is a certified manufacturer, importer, and distributor of medical cannabis flowers and full-spectrum extracts, as well as the first approved medical device for inhalable medical cannabis extracts with consistent dosing.

The focus of its daily activities is on providing the best possible medical care for patients. With its diverse range of medical cannabis and full-spectrum cannabis extracts, the company helps to improve the quality of life of patients as part of their treatment.

With more than eight years of experience in the field of medical cannabis, the company is one of the market leaders in Germany.

Further information: www.420pharma.de

Becanex GmbH

contact for Enquiries: Becanex GmbH, Sebastian Kamphorst (Geschäftsführer) sebastian@becanex.com

About Becanex GmbH

Becanex GmbH manufactures THC‑dominant and CBD‑dominant pharmaceutical Concentrates (70% THC and 62% CBD, respectively), marketed as the PIEX product portfolio. The concentrates are characterized by flowable viscosity and a representative cannabinoid and terpene profile — “the flower in a bottle.” PIEX Concentrates may serve as an alternative to inhaled dronabinol or cannabis flower and can be processed in pharmacies into capsules, suppositories, or standardized extracts for individualized patient treatment.
Becanex holds a manufacturing authorization under §13 (1) AMG, a GMP certificate, and is registered as an active substance manufacturer under §64 (3g) AMG at its Berlin production site.

Further information: www.becanex.com